Loading...

Yield10 Bioscience Inc
NASDAQ:YTEN

Watchlist Manager
Yield10 Bioscience Inc Logo
Yield10 Bioscience Inc
NASDAQ:YTEN
Watchlist
Price: 2.5 USD -6.02% Market Closed
Updated: Mar 25, 2023

Intrinsic Value

YTEN doesn't have a meaningful market cap.
YTEN's intrinsic value estimate is unreliable because it is based only on its DCF value.

The intrinsic value of one YTEN stock under the Base Case scenario is 2.2 USD. Compared to the current market price of 2.5 USD, Yield10 Bioscience Inc is Overvalued by 12%.

The Intrinsic Value is calculated as the average of the two valuation methods:

YTEN Intrinsic Value
Base Case
2.2 USD
Overvaluation 12%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

YTEN Profitability Score
Profitability Due Diligence

Yield10 Bioscience Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
19/100
Profitability
Score

Yield10 Bioscience Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

YTEN Solvency Score
Solvency Due Diligence

Yield10 Bioscience Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Long-Term Liabilities
Short-Term Liabilities
43/100
Solvency
Score

Yield10 Bioscience Inc's solvency score is 43/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
Yield10 Bioscience Inc

Current Assets 5M
Cash & Short-Term Investments 4.3M
Receivables 30k
Other Current Assets 641k
Non-Current Assets 3.1M
PP&E 2.7M
Other Non-Current Assets 331k
Current Liabilities 1.6M
Accounts Payable 109k
Accrued Liabilities 1.5M
Non-Current Liabilities 2.1M
Other Non-Current Liabilities 2.1M
Efficiency
0%
Gross Margin
-2 989%
Operating Margin
-3 015%
Net Margin
-2 568%
FCF Margin
-133%
ROE
-341%
ROIC
-107%
ROCE
Other

YTEN Capital Structure
Yield10 Bioscience Inc

Market Capitalization 12.2M USD
Total Debt 0 USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 2.4M USD
Short-Term Investments 2M USD
Enterprise Value 7.9M USD

Wall St
Price Targets

YTEN Price Targets Summary
Yield10 Bioscience Inc

Wall Street analysts forecast YTEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for YTEN is 14.96 USD with a low forecast of 7.07 USD and a high forecast of 26.25 USD.

Lowest
Price Target
7.07 USD
183% Upside
Average
Price Target
14.96 USD
498% Upside
Highest
Price Target
26.25 USD
950% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

YTEN Competitors
Yield10 Bioscience Inc

YTEN Suppliers & Customers
Yield10 Bioscience Inc

There is no information about
Yield10 Bioscience Inc
key suppliers
Customers Map

Ownership

YTEN Insider Trading
Buy and sell transactions by insiders

Yield10 Bioscience Inc insiders have only bought shares in the past 12 months.

During the last 12 months Yield10 Bioscience Inc insiders bought 16.8k USD , and have not sold any shares. The last transaction was made on Mar 25, 2023 by Sinskey Anthony J (Director), who bought 5.6k USD worth of YTEN shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
1
16.8k USD
9-12
months
No Insider Transactions
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
N/A
N/A
6 Months
N/A
N/A
N/A
9 Months
N/A
16.8k USD
16.8k
12 Months
N/A
16.8k USD
16.8k
Purchases
77
Sales
103
No transactions found
Why is insider trading important?

Shareholder Return

YTEN Return Decomposition
Main factors of price return

Price Return Decomposition
is not available

It is impossible to break down the market cap return as the net margin from 5 years ago is negative.

What is price return decomposition?

YTEN Price
Yield10 Bioscience Inc

1M 1M
-22%
6M 6M
-24%
1Y 1Y
-51%
3Y 3Y
-34%
5Y 5Y
-97%
Annual Price Range
2.5
52w Low
1.66
52w High
5.66
Price Metrics
Average Annual Return -42.97%
Standard Deviation of Annual Returns 30.65%
Max Drawdown -98%
Shares Statistics
Market Capitalization 12.2M USD
Shares Outstanding 5 074 090
Percentage of Shares Shorted 1.56%

Company Profile

Yield10 Bioscience Inc Logo
Yield10 Bioscience Inc

Country

United States of America

Industry

Biotechnology

Market Cap

12.2M USD

Dividend Yield

0%

Description

Yield10 Bioscience, Inc. operates as an agricultural bioscience company. The company is headquartered in Woburn, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2006-11-10. The firm is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low-carbon sustainable seed products. The firm focuses on petroleum replacement markets, in which it is developing Camelina oil for use as a biofuel feedstock and polyhydroxyalkanoates (PHA) bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and food and nutrition markets, in which it is developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets. The company is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits that form improved elite Camelina varieties for the biofuel market. The firm's new seed product traits include the PHA bioplastic trait developed by the Company and the omega-3 (DHA+EPA) oil traits.

Contact

MASSACHUSETTS
Woburn
19 Presidential Way Ste 201
+16175831700.0
http://www.yield10bio.com/

IPO

2006-11-10

Employees

29

Officers

Co-Founder, Pres, CEO & Director
Dr. Oliver P. Peoples
Co-Founder & Independent Director
Dr. Anthony J. Sinskey Ph.D., Sc.D.
VP of Research & Chief Science Officer
Dr. Kristi D. Snell
VP of Planning & Corp. Communications and Sec.
Ms. Lynne H. Brum
VP of Fin., Chief Accounting Officer & Treasurer
Mr. Charles B. Haaser
Director of Bus. Analytics & Operations
Dr. Nicholas Renegar Ph.D.

See Also

Similar Stocks
What is the Intrinsic Value of one YTEN stock?

The intrinsic value of one YTEN stock under the Base Case scenario is 2.2 USD.

Is YTEN stock undervalued or overvalued?

Compared to the current market price of 2.5 USD, Yield10 Bioscience Inc is Overvalued by 12%.